Veterinary Medicines

Equip FT Suspension injectable

Authorised
  • Equine influenza virus H3N8, A/equine/Kentucky/1/98, Inactivated
  • Equine influenza virus H7N7, A/equine/Newmarket/77, Inactivated
  • Clostridium tetani, toxoid
  • Equine influenza virus H3N8, A/Equine/Borlange/91, Inactivated
Download as PDF

Product identification

Medicine name:
Equip FT Suspension injectable
Equip FT Injektionssuspension
Active substance:
  • Equine influenza virus H3N8, A/equine/Kentucky/1/98, Inactivated
  • Equine influenza virus H7N7, A/equine/Newmarket/77, Inactivated
  • Clostridium tetani, toxoid
  • Equine influenza virus H3N8, A/Equine/Borlange/91, Inactivated
Target species:
  • Horse
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Equine influenza virus H3N8, A/equine/Kentucky/1/98, Inactivated
    2.40
    log10 haemagglutination inhibiting unit(s)
    /
    1.00
    Dose
  • Equine influenza virus H7N7, A/equine/Newmarket/77, Inactivated
    1.20
    log10 haemagglutination inhibiting unit(s)
    /
    1.00
    Dose
  • Clostridium tetani, toxoid
    70.00
    international unit(s)
    /
    1.00
    Dose
  • Equine influenza virus H3N8, A/Equine/Borlange/91, Inactivated
    2.10
    log10 haemagglutination inhibiting unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Horse
      • All relevant tissues
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI05AL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Available in:
  • Luxembourg
Package description:
  • Equip FT 10 2 ml Pre-filled syringe Suspension for injection
  • Equip FT 10 2 ml Vial Suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Ministere De La Sante Division De La Pharmacie Et Des Medicaments
Authorisation number:
  • V 087/17/08/1533
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 2/02/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."